Vaxart (VXRT) SVP Sean Tucker reports RSU tax-withholding disposition
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vaxart, Inc. senior executive Sean Tucker reported a routine tax-related share disposition tied to restricted stock unit vesting. On March 18, 2026, 8,072 shares of common stock were withheld by the company to cover income tax obligations from RSUs that vested on that date, a non-market transaction rather than an open-market sale. After this withholding, Tucker directly holds 923,153 common shares and has additional indirect holdings of 51,465 shares in joint tenancy with Frances Chang and 9,060 shares held by his spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Tucker Sean
Role
SVP, Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 8,072 | $0.6346 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 923,153 shares (Direct);
Common Stock — 51,465 shares (Indirect, By joint tenancy with Frances Chang and Sean Tucker)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Vaxart (VXRT) disclose for Sean Tucker?
Vaxart disclosed that SVP and Chief Scientific Officer Sean Tucker had 8,072 common shares withheld by the company to satisfy income tax obligations from vested RSUs on March 18, 2026, a routine tax-withholding disposition rather than an open-market sale.
Was the Vaxart (VXRT) Sean Tucker transaction an open-market sale?
No, the Sean Tucker transaction was not an open-market sale. The filing states 8,072 shares were withheld by Vaxart to cover income tax withholding and remittance obligations associated with the net settlement of RSUs that vested on March 18, 2026.
What does the F transaction code mean in the Vaxart (VXRT) Form 4?
The F code in the Form 4 indicates a tax-withholding disposition. In this case, 8,072 Vaxart common shares were withheld by the issuer to satisfy income tax obligations related to RSUs that vested on March 18, 2026, rather than being sold on the open market.
What role does Sean Tucker hold at Vaxart (VXRT) in this Form 4?
Sean Tucker is identified as an officer of Vaxart, serving as SVP and Chief Scientific Officer. The Form 4 reflects his equity compensation activity, specifically RSUs that vested on March 18, 2026, and the related tax-withholding share disposition by the company.